The effect of age and comorbidity on patient-centered health outcomes in patients receiving adjuvant chemotherapy for colon cancer
J Hermosillo-Rodriguez, DA Anaya, Y Sada… - Journal of Geriatric …, 2013 - Elsevier
OBJECTIVES: While the impact of age, comorbidity and receipt of adjuvant chemotherapy
on survival are known, less is known about their effect on patient-centered outcomes …
on survival are known, less is known about their effect on patient-centered outcomes …
[HTML][HTML] Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant …
T Suto, M Ishiguro, C Hamada, K Kunieda… - International journal of …, 2017 - Springer
Background Six months of adjuvant chemotherapy is regarded as the standard of care for
patients with stage III colon cancer. However, whether longer treatment can improve …
patients with stage III colon cancer. However, whether longer treatment can improve …
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy …
M Kotaka, S Iwamoto, H Satake, D Sakai… - International Journal of …, 2020 - Springer
Background Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as
adjuvant chemotherapy is under debate. REACT study aimed to investigate the efficacy of …
adjuvant chemotherapy is under debate. REACT study aimed to investigate the efficacy of …
[HTML][HTML] Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective …
Q Yu, Z Li, Y Liu, Y Luo, J Fan, P Xie, X Cao, X Chen… - Current …, 2023 - mdpi.com
(1) Background: The duration of adjuvant chemotherapy recommended by the NCCN
guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy …
guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy …
Administration of adjuvant chemotherapy in older patients with stage III colon cancer: an observational study
CBM van den Broek, C Puylaert, AJ Breugom… - Colorectal …, 2017 - Wiley Online Library
Aim According to established guidelines, patients with Stage III colon cancer should receive
adjuvant chemotherapy. However, a significant proportion do not. This study assessed …
adjuvant chemotherapy. However, a significant proportion do not. This study assessed …
[HTML][HTML] CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial
F Liu, L Yang, Y Wu, C Li, J Zhao… - Chinese Journal of …, 2016 - ncbi.nlm.nih.gov
Objective The aim of this prospective, single-arm phase II trial was to confirm the safety and
efficacy of neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX) …
efficacy of neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX) …
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the …
C Tournigand, T André, F Bonnetain… - Journal of clinical …, 2012 - ascopubs.org
Purpose Oxaliplatin combined with fluoropyrimidine improves survival in patients with stage
III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II …
III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II …
The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II–III Colorectal Cancer: A Retrospective …
L Liu, X Pang, K Zhao, Y Chen, Y Li, R You… - … Journal of General …, 2023 - Taylor & Francis
Background It is common for elderly patients to be underrepresented in clinical trials for
cancer, which can result in a lack of efficacy data and unclear criteria to guide treatment …
cancer, which can result in a lack of efficacy data and unclear criteria to guide treatment …
Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC)
MC Cripps, M Vincent, D Jonker, I Kerr… - Journal of Clinical …, 2005 - ascopubs.org
3577 Background: Combination chemotherapy results in improved outcomes in trials of
selected fit patients with ACRC. For older, less fit, more complicated patients, combination …
selected fit patients with ACRC. For older, less fit, more complicated patients, combination …
[HTML][HTML] Efficacy and safety of capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer: An observational study from a tertiary cancer center in South India
AV Kalidindi, B Dubashi, M Jayanthi… - Indian Journal of …, 2022 - journals.lww.com
Background 5-fluorouracil (5-FU) was the standard treatment care for colorectal cancer
(CRC), however, its efficacy was limited due to safety concerns. Capecitabine and …
(CRC), however, its efficacy was limited due to safety concerns. Capecitabine and …